Press Release

Harbour BioMed Appoints Amy Que, PhD, as Chief Technology Officer

June 22, 2021

Harbour BioMed
on WeChat

Back to list

Harbour BioMed Appoints Amy Que, PhD, as Chief Technology Officer

June 22, 2021

Harbour BioMed (HBM) announced the appointment of Dr. Amy Que as Chief Technology Officer (CTO). Dr. Que will lead the Chemistry, Manufacture and Control (CMC) group and oversee all the CMC-related activities and supply chain management. In this strategic role, she will be responsible for strategic leadership, technical expertise and specialized knowledge in GMP manufacturing of protein therapeutics for drug development and commercialization.


Dr. Que joins HBM with more than 20 years’ extensive experience in leading projects through CMC development and clinical development, regulatory filing, GMP/PAI inspection towards NDA approval, with executive leadership roles in well-known international companies, including Pfizer and Wuxi biologics. Prior to joining HBM, Dr. Que served ad Senior VP, Project Management and Alliance Management at Innovent Biologics.

Dr. Que graduated from University of British Columbia with Master Degree in Analytical Chemistry and Indiana University Bloomington with PhD in Chemistry.



About Harbour BioMed

Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on oncology and immunology. The Company is building its robust portfolio and differentiated pipeline through internal R&D capability, collaborations with co-discovery and co-development partners and select acquisitions.

The Company’s proprietary antibody technology platforms Harbour Mice® generate fully human monoclonal antibodies in two heavy and two light chain (H2L2) format, as well as heavy chain only (HCAb) format. Building upon the HCAb antibodies, the HCAb-based immune cell engagers (HBICE®) are capable of delivering tumor killing effects unachievable by traditional combination therapies. Integrating Harbour Mice® with single B cell cloning platform, our antibody discovery engine is highly unique and efficient for development of next generation therapeutic antibodies.  


For more information, please visit

Media Contact:

Harbour BioMed Public Relations